Objective To investigate the clinical efficacy of bifidobacterium in the adjuvant treatment of hepatitis B cirrhosis patients with the Type 2 Diabetes Mellitus(T2DM)and its effects on liver function,immune function and blood glucose.Methods A total of 138 cases of hepatitis B cirrhosis with diabetes mellitus admitted to The First Affiliated Hospital of Anhui Medical University from March 2020 to March 2024 were randomly divided into experimental group and control group,with 69 cases in each group.Both groups were given symptomatic treatment such as conventional antiviral,liver protection,enzyme lowering,insulin aspartate to control blood sugar,etc.The experimental group additionally recevied bifidobacterium Lactobacillus triple viable tablet.Both groups were treated and observed continuously for 3 months.Results Compared with before treatment,blood glucose in 2 groups was controlled within the normal range,ALT,AST,TBIL,HbA1c levels were significantly improved,with significant differences(P＜0.05).After treatment,the levels of CD4+、CD8+、CD4+/CD8+and Pro-ALB in both groups were higher than those before treatment,and the experimental group was better than the control group(P＜0.05).The total effective rate of the experimental group was significantly higher than that of the control group(95.65％vs.84.05％,P＜0.05).Total bilirubin(TBIL),aspartate aminotransferase(AST),alanine aminotransferase(ALT)and prealbumin(Pro-ALB)were significantly decreased in 2 groups(P＜0.05).The levels of CD4+、CD8+and CD4+/CD8+of T lymphocyte subsets were improved,and the above indexes were improved more significantly in the experimental group(P＜0.05).The incidence of complications in the experimental group was significantly lower than that in the control group(P＜0.05).Conclusion Bifidobacterium adjuvant therapy for hepatitis B cirrhosis complicated with diabetes can improve liver function,promote liver function recovery,improve immune function,effectively control blood sugar,reduce complication rate,and effectively alleviate clinical symptoms of patients,which is worthy of clinical promotion.
hepatitis B cirrhosisbifidobacteriumliver functionimmune functiontype 2 diabetes mellitus
维普
万方数据
